Rowlandmiller & PARTNERS.ADV Sells 290 Shares of Zoetis Inc. (NYSE:ZTS)

Rowlandmiller & PARTNERS.ADV cut its stake in shares of Zoetis Inc. (NYSE:ZTS) by 10.9% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm owned 2,363 shares of the company’s stock after selling 290 shares during the quarter. Rowlandmiller & PARTNERS.ADV’s holdings in Zoetis were worth $385,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Darwin Wealth Management LLC bought a new position in shares of Zoetis during the third quarter valued at $31,000. First Personal Financial Services bought a new position in shares of Zoetis during the third quarter valued at $33,000. Capital Performance Advisors LLP bought a new position in shares of Zoetis during the third quarter valued at $33,000. Dunhill Financial LLC lifted its holdings in shares of Zoetis by 80.6% during the third quarter. Dunhill Financial LLC now owns 168 shares of the company’s stock valued at $33,000 after acquiring an additional 75 shares during the period. Finally, Atlantic Edge Private Wealth Management LLC lifted its holdings in shares of Zoetis by 482.8% during the fourth quarter. Atlantic Edge Private Wealth Management LLC now owns 169 shares of the company’s stock valued at $28,000 after acquiring an additional 140 shares during the period. 92.80% of the stock is owned by institutional investors.

Zoetis Trading Up 1.9 %

Shares of ZTS stock opened at $160.39 on Monday. The stock has a market cap of $71.82 billion, a price-to-earnings ratio of 29.32, a PEG ratio of 2.78 and a beta of 0.90. The stock has a 50-day moving average of $166.51 and a 200-day moving average of $177.94. The company has a current ratio of 1.75, a quick ratio of 1.08 and a debt-to-equity ratio of 1.09. Zoetis Inc. has a 1-year low of $144.80 and a 1-year high of $200.53.

Zoetis (NYSE:ZTS) last released its earnings results on Thursday, February 13th. The company reported $1.40 EPS for the quarter, topping the consensus estimate of $1.37 by $0.03. The business had revenue of $2.32 billion during the quarter, compared to analysts’ expectations of $2.30 billion. Zoetis had a return on equity of 53.82% and a net margin of 26.86%. On average, equities research analysts forecast that Zoetis Inc. will post 6.07 earnings per share for the current year.

Zoetis Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Tuesday, June 3rd. Investors of record on Monday, April 21st will be given a dividend of $0.50 per share. The ex-dividend date is Monday, April 21st. This represents a $2.00 annualized dividend and a dividend yield of 1.25%. Zoetis’s payout ratio is 36.56%.

Insiders Place Their Bets

In other news, EVP Roxanne Lagano sold 326 shares of the company’s stock in a transaction on Tuesday, February 11th. The stock was sold at an average price of $171.18, for a total transaction of $55,804.68. Following the transaction, the executive vice president now owns 16,107 shares of the company’s stock, valued at $2,757,196.26. This represents a 1.98 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders own 0.16% of the company’s stock.

Wall Street Analyst Weigh In

A number of analysts have recently weighed in on the company. Piper Sandler lowered their target price on Zoetis from $210.00 to $200.00 and set an “overweight” rating for the company in a research note on Monday, February 10th. Stifel Nicolaus decreased their target price on Zoetis from $210.00 to $180.00 and set a “buy” rating for the company in a research report on Tuesday, January 7th. Leerink Partnrs upgraded Zoetis to a “strong-buy” rating in a research report on Monday, December 2nd. UBS Group started coverage on Zoetis in a report on Monday, December 9th. They set a “neutral” rating and a $196.00 price objective on the stock. Finally, Barclays lifted their price objective on Zoetis from $242.00 to $244.00 and gave the company an “overweight” rating in a report on Friday, February 14th. One investment analyst has rated the stock with a hold rating, nine have assigned a buy rating and two have issued a strong buy rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Buy” and a consensus price target of $215.40.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.